Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis. Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15708. Epub ahead of print. PMID: 38899553.